Cumulative Live Birth Rate With eSET After Preimplantation Genetic Screening Versus Conventional In-vitro Fertilization

Inclusion Criteria:

1. Women who are participating in their first cycle of IVF or ICSI

2. Women ages 20 to 37 years.

3. Women who obtain 3 or more good-quality blastocysts defined as morphological score ofinner cell mass B or A, trophectoderm C or better, and grade 4 or better on day 5 ofembryo culture will be randomized.

Exclusion Criteria:

1. Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis,submucous myoma, or endo-metrial polyp(s); or with history of intrauterine adhesions.

2. Women with untreated hydrosalpinx;

3. Women who are indicated and planned to undergo PGD, for example, parental abnormalkaryo-type or diagnosed with monogenic disease;

4. Women who use donated oocytes or sperm to achieve pregnancy;

5. Women with contraindication for assisted reproductive technology or for pregnancy,such as poorly controlled Type I or Type II diabetes; undiagnosed liver disease ordysfunction (based on se-rum liver enzyme testing); renal disease or abnormal serumrenal function; significant anemia; history of deep venous thrombosis, pulmonaryembolus, or cerebrovascular accident; uncontrolled hyper-tension, known symptomaticheart disease; history of or suspected cervical carcinoma, endometrial carcinoma, orbreast carcinoma; undiagnosed vaginal bleeding.